ArticleProtist2014
A unique hexokinase in Cryptosporidium parvum, an apicomplexan pathogen lacking the Krebs cycle and oxidative phosphorylation.
Article in Protist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Multiple pathways for glucose phosphate transport and utilization support growth of Cryptosporidium parvum.Nature communications · 2024Article
- Structural Analysis ofInternational journal of molecular sciences · 2023Article
- Multiple pathways for glucose phosphate transport and utilization support growth ofbioRxiv : the preprint server for biology · 2023Article
- Cryptosporidium parvumcompetes with the intestinal epithelial cells for glucose and impairs systemic glucose supply in neonatal calves.Veterinary research · 2023Article
- Protein kinases on carbon metabolism: potential targets for alternative chemotherapies against toxoplasmosis.Frontiers in cellular and infection microbiology · 2023Review
- An update onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- 2-Deoxy-D-glucose and combined 2-Deoxy-D-glucose/albendazole exhibit therapeutic efficacy against Echinococcus granulosus protoscoleces and experimental alveolar echinococcosis.PLoS neglected tropical diseases · 2022Article
- High-throughput and reliable acquisition ofSynthetic and systems biotechnology · 2022Article
- The Oesophageal Squamous Cell Carcinoma Cell Line COLO-680N Fails to Support SustainedPathogens (Basel, Switzerland) · 2021Article
- Implication of Potential Differential Roles of the Two Phosphoglucomutase Isoforms in the Protozoan ParasitePathogens (Basel, Switzerland) · 2021Article
- Cryptosporidiosis Modulates the Gut Microbiome and Metabolism in a Murine Infection Model.Metabolites · 2021Article
- Metabolic Signatures ofBiology · 2021Article
- Identification of potential drug target in malarial disease using molecular docking analysis.Saudi journal of biological sciences · 2020Article
- Cryptosporidium parvum alters glucose transport mechanisms in infected enterocytes.Parasitology research · 2019Article
- An overview of structure, function, and regulation of pyruvate kinases.Protein science : a publication of the Protein Society · 2019Review
- The Action of the Hexokinase Inhibitor 2-deoxy-d-glucose on Cryptosporidium parvum and the Discovery of Activities against the Parasite Hexokinase from Marketed Drugs.The Journal of eukaryotic microbiology · 2019Article
- Heterologous overexpression of active hexokinases from microsporidia Nosema bombycis and Nosema ceranae confirms their ability to phosphorylate host glucose.Parasitology research · 2019Article
- Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.International journal for parasitology. Drugs and drug resistance · 2018Article
- Molecular and biochemical characterization of Eimeria tenella hexokinase.Parasitology research · 2016Article
- Metabolic signatures of Besnoitia besnoiti-infected endothelial host cells and blockage of key metabolic pathways indicate high glycolytic and glutaminolytic needs of the parasite.Parasitology research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Cryptosporidium parvum may cause virtually untreatable infections in AIDS patients, and is recently identified as one of the top four diarrheal pathogens in children in developing countries. Cryptosporidium differs from other apicomplexans (e.g., Plasmodium and Toxoplasma) by lacking many metabolic pathways including the Krebs cycle and cytochrome-based respiratory chain, thus relying mainly on glycolysis for ATP production. Here we report the molecular and biochemical characterizations of a hexokinase in C. parvum (CpHK). Our phylogenetic reconstructions indicated that apicomplexan hexokinases including CpHK were highly divergent from those of humans and animals (i.e., at the base of the eukaryotic clade). CpHK displays unique kinetic features that differ from those in mammals and Toxoplasma gondii (TgHK) in the preference towards various hexoses and its capacity to use ATP and other NTPs. CpHK also displays substrate inhibition by ATP. Moreover, 2-deoxy-D-glucose (2DG) could not only inhibit the CpHK activity, but also the parasite growth in vitro at concentrations nontoxic to host cells (IC(50) = 0.54 mM). While the exact action of 2-deoxy-D-glucose on the parasite is subject to further verification, our data suggest that CpHK and the glycolytic pathway may be explored for developing anti-cryptosporidial therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.